18 F-Fluoromisonidazole in tumor hypoxia imaging

Zuoyu Xu; Xiao-Feng Li; Hongyan Zou; Xilin Sun; Baozhong Shen

doi:10.18632/oncotarget.21662

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

¹⁸F-Fluoromisonidazole in tumor hypoxia imaging

Zuoyu Xu, Xiao-Feng Li, Hongyan Zou, Xilin Sun and Baozhong Shen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:94969-94979. https://doi.org/10.18632/oncotarget.21662

Metrics: PDF 2612 views | HTML 3495 views | ?

Abstract

Zuoyu Xu1,2, Xiao-Feng Li1,2, Hongyan Zou1, Xilin Sun1,2 and Baozhong Shen1,2

1Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China

2TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Correspondence to:

Baozhong Shen, email: [email protected]

Xilin Sun, email: [email protected]

Keywords: hypoxia, ¹⁸F-Fluoromisonidazole, PET, tumor

Received: June 28, 2017 Accepted: September 21, 2017 Published: October 07, 2017

ABSTRACT

Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. ¹⁸F-Fluoromisonidazole positron emission tomography (¹⁸F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between ¹⁸F-FMISO PET and other detection methods, current applications of ¹⁸F-FMISO PET and the development prospects of this imaging technology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21662

Publication Alerts

Reviews:

18F-Fluoromisonidazole in tumor hypoxia imaging

Abstract

¹⁸F-Fluoromisonidazole in tumor hypoxia imaging